US20080194649A1 - Ophthalmologic Compositions And Use Mode Thereof - Google Patents

Ophthalmologic Compositions And Use Mode Thereof Download PDF

Info

Publication number
US20080194649A1
US20080194649A1 US11/908,161 US90816106A US2008194649A1 US 20080194649 A1 US20080194649 A1 US 20080194649A1 US 90816106 A US90816106 A US 90816106A US 2008194649 A1 US2008194649 A1 US 2008194649A1
Authority
US
United States
Prior art keywords
agent
pharmaceutical composition
parasympatholytic
local anaesthetic
phenylephrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/908,161
Other languages
English (en)
Inventor
Walild Khatib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Thea SAS
Original Assignee
Laboratoires Thea SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Thea SAS filed Critical Laboratoires Thea SAS
Assigned to LABORATOIRES THEA reassignment LABORATOIRES THEA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHATIB, WALID
Publication of US20080194649A1 publication Critical patent/US20080194649A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the present invention concerns the therapeutic field and more particularly the ophthalmologic field.
  • compositions based on a parasympatholytic agent, an adrenergic substance and advantageously a local anaesthetic in the context of pre-operative treatment of the eye for a surgical operation on cataracts or laser treatment of the retina.
  • active ingredients are to be administered simultaneously on or in the eye.
  • the parasympatholytic agent is a mydriatic agent and preferably a derivative of tropic acid such as a tropic acid ester or a tropic acid amide or a cyclohexyl or cyclopentylacetic acid amide.
  • parasympatholytic agents we shall notably mention cyclodrine, eucatropine, homatropine as well as atropine (benzylic ester of tropic acid), N-methyl hyoscine and especially tropicamide (N-ethyl 2-phenyl N-4 pyridyl methyl hydracrylamide or pyridyl methyl benzene acetamide).
  • butocaine prilocaine, procaine, novocaine, tetracaine, ambucaine, amylocaine, bupivacaine, carticaine, butoxycaine, formocaine, mepivacaine, etidocaine, prilocaine, orthocaine, oxybuprocaine or benoxinate, and mainly lidocaine or diethylamino 2,6 dimethyl acetanilide, or one of its salts.
  • noradrenaline phenylephrine, isoprenaline, dipivefrine, dimetrophine, norfenefrine, pholedrine or octedrine.
  • compositions according to the invention are of major interest, notably in intracameral injection, for preparing the eye before a surgical operation or during the surgical operation, notably in the surgical treatment of cataracts.
  • the volume of the intracameral chamber does not exceed 300 ⁇ l in man
  • the volume of the composition injected should preferably be less than or equal to 200 ⁇ l, notably between 50 and 200 ⁇ l.
  • compositions according to the invention can also be administered in a collyrium beforehand or during a laser intervention on the retina.
  • 1 to 5 drops are instilled, which also represents a volume less than or equal to 200 ⁇ l.
  • compositions according to the invention are capable of providing very rapid anaesthesia as well as nearly instantaneous, sizeable and sustainable dilation of the pupil for undertaking an examination of the pupil and the surgical operation as quickly as possible.
  • anaesthesia is of long duration, so that the subject suffers little from the operation they undergo.
  • Such a combination has the advantage of reinforcing the mydriatic effect of the parasympatholytic derivative, but without manifesting an overly long effect which leads to a decrease in vision essentially characterised by prolonged mydriasis.
  • the effects of mydriasis mainly translate into disturbances of vision and balance.
  • compositions according to the invention can be distinguished from those described in the prior art by a concentration of a sympathomimetic agent, for example phenylephrine, that is sharply reduced.
  • a concentration of a sympathomimetic agent for example phenylephrine
  • the concentration of the parasympatholytic agent is also reduced.
  • a combination of just two mydriatic agents is thus distinguished from the solutions in the prior art by low concentrations of sympathomimetic agents, or even parasympatholytic agents.
  • composition according to the invention also contains a local anaesthetic agent.
  • compositions according to the invention contain between 0.001 and 0.6% parasympatholytic agent, between 0.04 and 0.5% sympathomimetic agent, and possibly between 0.2 and 3% local anaesthetic agent.
  • a preferred composition contains between 0.01 and 0.5% parasympatholytic agent defined above, between 0.5 and 1.5% local anaesthetic and between 0.1 and 0.4% sympathomimetic agent.
  • An ophthalmologic composition according to the invention contains between 0.015 and 0.025% parasympatholytic agent, advantageously tropicamide, between 0.75% and 1.25% lidocaine and between 0.2 and 0.4% phenylephrine in a single preparation.
  • parasympatholytic agent advantageously tropicamide
  • lidocaine between 0.2 and 0.4% phenylephrine
  • Such a formulation is particularly well suited to injection into the anterior chamber of the eye before the surgical treatment of cataracts. For this, an incision is made at the time of the operation in the anterior chamber of the eye and the composition is injected into it. This preparation of the eye simultaneously causes mydriasis and local anaesthesia, allowing the later extraction of the lens under favourable conditions. In this precise case, a single injection of a volume of the preparation between 0.05 and 0.2 ml provides the desired effect.
  • the concentrations of the pharmaceutical compositions instilled are advantageously adapted.
  • the concentrations of the parasympatholytic agent and local anaesthetic agent will be significantly higher, in the higher values of the widest range of concentrations.
  • the concentrations of the parasympatholytic agent will be between 0.1 and 0.25% and the concentration of the local anaesthetic agent will be between 2 and 3%.
  • Such preparations being designed for a single use, the use of a preservative may not be necessary.
  • the preparations according to the invention therefore may not contain any preservatives.
  • the method of administration may also be different, proceeding with the instillation of the preparation on the treated eye in two to four times at one minute intervals. Thus, sedation of pain is ensured more immediately and for a longer time.
  • the three active ingredients are dissolved or dispersed in an aqueous vehicle, advantageously sterile.
  • the compositions according to the invention may come in liquid or solid form, for example in the form of collyriums, single-dose recipients, instillable preparations, ready-to-use or in freeze-dried form to be reconstituted with an aqueous solvent when used.
  • compositions according to the invention may also come in a mixed form, for example one of the active ingredients being freeze-dried to be reconstituted by adding an aqueous solution containing the other active ingredients. It is also possible to have a bottle containing one of the solid active ingredients, covered by a frangible membrane above which can be found the solution containing the other active ingredients.
  • the preparation according to the invention is to be administered by injection into the anterior chamber of the eye (intracameral zone).
  • Said preparation could be presented in a single packaging for easy handling with total safety, then administered to the patient in a quantity of liquid less than 1 ml, typically between 50 and 200 ⁇ l.
  • the preparation is used under the same conditions as in example 1.
  • Said preparation will be presented in single-use packaging. This collyrium is particularly well suited to the treatment of pain during laser treatment.
  • the collyriums according to the invention are to be instilled on the eye, in three times one drop during the same day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US11/908,161 2005-03-09 2006-03-09 Ophthalmologic Compositions And Use Mode Thereof Abandoned US20080194649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0502357A FR2882930B1 (fr) 2005-03-09 2005-03-09 Nouvelles compositions ophtalmologiques et leur mode d'utilisation
FR0502357 2005-03-09
PCT/FR2006/000528 WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000528 A-371-Of-International WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/464,524 Division US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Publications (1)

Publication Number Publication Date
US20080194649A1 true US20080194649A1 (en) 2008-08-14

Family

ID=35058756

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/908,161 Abandoned US20080194649A1 (en) 2005-03-09 2006-03-09 Ophthalmologic Compositions And Use Mode Thereof
US13/464,524 Active 2027-05-03 US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/464,524 Active 2027-05-03 US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Country Status (26)

Country Link
US (2) US20080194649A1 (ja)
EP (1) EP1858481B1 (ja)
JP (1) JP2008532985A (ja)
KR (1) KR20070111501A (ja)
CN (1) CN101151018A (ja)
CA (1) CA2598503C (ja)
CY (2) CY1121865T1 (ja)
DK (1) DK1858481T3 (ja)
ES (1) ES2728071T3 (ja)
FR (1) FR2882930B1 (ja)
HR (1) HRP20191044T1 (ja)
HU (1) HUE043668T2 (ja)
IL (1) IL185197A0 (ja)
LT (2) LT1858481T (ja)
LU (1) LUC00136I2 (ja)
MA (1) MA29269B1 (ja)
MX (1) MX2007010295A (ja)
NL (1) NL301017I2 (ja)
NO (2) NO339793B1 (ja)
PL (1) PL1858481T3 (ja)
PT (1) PT1858481T (ja)
RU (1) RU2392925C2 (ja)
SI (1) SI1858481T1 (ja)
TN (1) TNSN07343A1 (ja)
TR (1) TR201908487T4 (ja)
WO (1) WO2006095095A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111029A3 (en) * 2011-02-18 2012-10-18 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
US9066856B2 (en) 2012-10-24 2015-06-30 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
CN103159672A (zh) * 2012-07-16 2013-06-19 湖南尔文生物科技有限公司 一种托品酰胺的制备方法
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
JP2016532723A (ja) * 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
US10285957B2 (en) 2016-08-25 2019-05-14 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
RU2649534C1 (ru) * 2017-05-10 2018-04-03 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ анестезии при факоэмульсификации катаракты
RU2662423C1 (ru) * 2017-07-26 2018-07-25 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ проведения обезболивания при выполнении витреоретинальных операций

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780760B2 (ja) * 1986-07-28 1995-08-30 ライオン株式会社 安定化されたフエニレフリン系液剤
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US6319240B1 (en) * 1999-05-25 2001-11-20 Iomed, Inc. Methods and apparatus for ocular iontophoresis
JP2004500906A (ja) * 1999-11-12 2004-01-15 ルーベン，　レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
JP4150846B2 (ja) * 2001-03-28 2008-09-17 参天製薬株式会社 ステロイドを有効成分とする網脈絡膜疾患治療剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2012111029A3 (en) * 2011-02-18 2012-10-18 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
EP2675455A2 (en) * 2011-02-18 2013-12-25 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
US9066856B2 (en) 2012-10-24 2015-06-30 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9486406B2 (en) 2012-10-24 2016-11-08 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9855246B2 (en) 2012-10-24 2018-01-02 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Also Published As

Publication number Publication date
NO339793B1 (no) 2017-01-30
LUC00136I1 (ja) 2019-11-04
LTPA2019017I1 (lt) 2019-12-10
CN101151018A (zh) 2008-03-26
DK1858481T3 (da) 2019-06-03
EP1858481A1 (fr) 2007-11-28
TR201908487T4 (tr) 2019-07-22
CA2598503C (fr) 2014-01-28
TNSN07343A1 (fr) 2008-12-31
RU2007137115A (ru) 2009-04-20
SI1858481T1 (sl) 2019-08-30
US20120220637A1 (en) 2012-08-30
RU2392925C2 (ru) 2010-06-27
HRP20191044T1 (hr) 2019-09-06
FR2882930A1 (fr) 2006-09-15
CA2598503A1 (fr) 2006-09-14
MA29269B1 (fr) 2008-02-01
KR20070111501A (ko) 2007-11-21
IL185197A0 (en) 2008-01-06
CY2019042I2 (el) 2020-05-29
CY1121865T1 (el) 2020-05-29
LT1858481T (lt) 2019-07-10
WO2006095095A1 (fr) 2006-09-14
CY2019042I1 (el) 2020-05-29
NL301017I2 (nl) 2020-04-30
JP2008532985A (ja) 2008-08-21
PL1858481T3 (pl) 2019-09-30
NO2017008I1 (no) 2017-03-24
ES2728071T3 (es) 2019-10-22
MX2007010295A (es) 2007-12-11
NL301017I1 (nl) 2019-11-06
LUC00136I2 (ja) 2021-02-12
NO20074850L (no) 2007-09-24
EP1858481B1 (fr) 2019-05-08
BRPI0607416A2 (pt) 2009-09-08
FR2882930B1 (fr) 2009-03-27
HUE043668T2 (hu) 2019-08-28
PT1858481T (pt) 2019-06-14
NO2017008I2 (no) 2017-03-24
US9289399B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
US9289399B2 (en) Ophthalmologic compositions and use mode thereof
CA2423354C (en) Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US20230355551A1 (en) Stabilization of epinephrine formulations
JP5736635B2 (ja) ドライアイ治療剤
US11925608B2 (en) Stabilization of epinephrine formulations
US20180055790A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3445331B1 (en) Preservative free pharmaceutical ophthalmic compositions
US20050080043A1 (en) Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP1283043B1 (en) Ophthalmic solution
CA2622418A1 (en) Indanylamines and their use for local anesthesia and chronic pain
US20160089375A1 (en) Topical ocular analgesic agents
US20210346318A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JPS588013A (ja) 緑内障および高眼圧症の治療用薬学的調合物
WO2018144786A1 (en) Antibiotic solution and method of injection to prevent ophthalmic infections
BRPI0607416B1 (pt) Composição farmacêutica para administração intracameral compreendendo uma combinação de agentes parasimpatolítico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento
Potter et al. Ocular and cardiac β-antagonism by timolol prodrugs, timolol and levobunolol
JPH0383931A (ja) 低刺激性ｇｒｆ経鼻投与製剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABORATOIRES THEA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHATIB, WALID;REEL/FRAME:019801/0767

Effective date: 20070723

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION